No quarterly revenue total was found in Jade Biosciences, Inc.'s SEC filings.
Jade Biosciences, Inc. (JBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $461.2 million in cash and investments and $761,000 in total debt.
Revenue
—
Net income
$-55.77M
-73.5% vs year-ago quarter
Operating cash flow
$-43.66M
-116.6% vs year-ago quarter
Free cash flow
$-33.65M
-50.8% vs prior quarter
EPS
$-0.76
+11.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
63.60M
+94.9% vs year-ago quarter
Net cash
$460.44M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1798749
- Former names
- Aerovate Therapeutics, Inc. (until Apr 30, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$58.9M | -$43.4M | -$35.0M | -$27.4M | -$27.8M |
| Net income | -$55.8M | -$40.4M | -$31.9M | -$25.2M | -$32.1M |
| Diluted EPS | -$0.76 | -$0.57 | -$0.50 | -$0.48 | -$0.86 |
| Operating cash flow | -$43.7M | -$24.1M | -$33.6M | -$22.1M | -$20.2M |
| Free cash flow | — | — | -$33.7M | -$22.3M | -$20.3M |
| Total assets | $472.1M | $319.4M | $349.8M | $202.4M | $224.0M |
| Total liabilities | $32.2M | $23.0M | $17.3M | $23.1M | $22.4M |
| Stockholders' equity | $439.9M | $296.5M | $332.5M | $179.3M | $201.6M |
| Cash and investments | $461.2M | $311.3M | $336.2M | $198.9M | $220.9M |
| Total debt | $761,000 | $808,000 | $851,000 | $867,000 | $811,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 1, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 26, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 11, 2026 | Jun 8, 2026 |
All 509 Jade Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.